Biomarkers for systemic therapy in ovarian cancer

Current Cancer Drug Targets

Volumn 14, Issue 3, 2014, Pages 259-273

  Pénzváltó, Zsófia ^a   Surowiak, Pawel ^b   Gyorffy, Balázs ^c,d  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^d SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Biomarkers; Ovarian cancer; Platinum; Resistance; Survival; Systemic therapy; Taxane

Indexed keywords

ALTRETAMINE; ANASTROZOLE; ANTINEOPLASTIC METAL COMPLEX; BETA TUBULIN; BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ETOPOSIDE; GEMCITABINE; GLUCURONOSYLTRANSFERASE 1A1; IFOSFAMIDE; LETROZOLE; LEUPRORELIN; MEGESTROL ACETATE; OLAPARIB; OXALIPLATIN; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; THIOPURINE METHYLTRANSFERASE; TOPOTECAN; UNINDEXED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ARTICLE; CANCER HORMONE THERAPY; CELLULAR DRUG CONCENTRATION; CELLULAR RESPONSE; CELLULAR STRESS RESPONSE; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DNA POLYMORPHISM; DNA REPAIR; DRUG CONCENTRATION; DRUG RESISTANCE; DRUG RESPONSE; DRUG TISSUE LEVEL; GENE; HUMAN; HYPERTENSION; META ANALYSIS (TOPIC); MICROTUBULE; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SYSTEMIC THERAPY; FEMALE; METABOLISM; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PREGNANCY;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PREGNANCY; TUMOR MARKERS, BIOLOGICAL;

EID: 84903736170     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009614666140310120107     Document Type: Article

References (152)

1. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2013. CA: Cancer J. Clin. 2013, 63 (1), 11-30.
2. Miller, D. S.; Blessing, J. A.; Krasner, C. N.; Mannel, R. S.; Hanjani, P.; Pearl, M. L.; Waggoner, S. E.; Boardman, C. H. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J. Clin. Oncol. 2009, 27 (16), 2686-2691.
3. McGuire, W. P.; Hoskins, W. J.; Brady, M. F.; Kucera, P. R.; Partridge, E. E.; Look, K. Y.; Clarke-Pearson, D. L.; Davidson, M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 1996, 334 (1), 1-6.
4. National Comprehensive Cancer Network http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf (Accessed October 15, 2013).
5. Ozols, R. F.; Bundy, B. N.; Greer, B. E.; Fowler, J. M.; Clarke- Pearson, D.; Burger, R. A.; Mannel, R. S.; DeGeest, K.; Hartenbach, E. M.; Baergen, R. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 2003, 21 (17), 3194-3200.
6. Markman, M.; Hoskins, W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J. Clin. Oncol. 1992, 10 (4), 513-514.
7. Stordal, B.; Pavlakis, N.; Davey, R. A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat. Rev. 2007, 33 (8), 688-703.
8. Siddik, Z. H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22 (47), 7265-7279.
9. Galluzzi, L.; Senovilla, L.; Vitale, I.; Michels, J.; Martins, I.; Kepp, O.; Castedo, M.; Kroemer, G. Molecular mechanisms of cisplatin resistance. Oncogene 2012, 31 (15), 1869-1883.
10. Safaei, R. Role of copper transporters in the uptake and efflux of platinum containing drugs. Cancer Lett. 2006, 234 (1), 34-39.
11. Blair, B. G.; Larson, C. A.; Safaei, R.; Howell, S. B. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clin. Cancer Res. 2009, 15 (13), 4312-4321.
12. Ishida, S.; Lee, J.; Thiele, D. J.; Herskowitz, I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc. Natl. Acad. Sci. U. S. A. 2002, 99 (22), 14298-14302.
13. Lee, Y. Y.; Choi, C. H.; Do, I. G.; Song, S. Y.; Lee, W.; Park, H. S.; Song, T. J.; Kim, M. K.; Kim, T. J.; Lee, J. W.; Bae, D. S.; Kim, B. G. Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy. Gynecol. Oncol. 2011, 122 (2), 361-365.
14. Ishida, S.; McCormick, F.; Smith-McCune, K.; Hanahan, D. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 2010, 17 (6), 574-583.
15. Chen, H. H.; Kuo, M. T. Overcoming platinum drug resistance with copper-lowering agents. Anticancer Res. 2013, 33 (10), 4157-4161.
16. Fu, S.; Naing, A.; Fu, C.; Kuo, M. T.; Kurzrock, R. Overcoming platinum resistance through the use of a copper-lowering agent. Mol. Cancer Ther. 2012, 11 (6), 1221-1225.
17. Nakayama, K.; Kanzaki, A.; Ogawa, K.; Miyazaki, K.; Neamati, N.; Takebayashi, Y. Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP. Int. J. Cancer 2002, 101 (5), 488-495.
18. Nakayama, K.; Kanzaki, A.; Terada, K.; Mutoh, M.; Ogawa, K.; Sugiyama, T.; Takenoshita, S.; Itoh, K.; Yaegashi, N.; Miyazaki, K.; Neamati, N.; Takebayashi, Y. Prognostic value of the Cutransporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy. Clin. Cancer Res. 2004, 10 (8), 2804-2811.
19. Mayr, D.; Pannekamp, U.; Baretton, G. B.; Gropp, M.; Meier, W.; Flens, M. J.; Scheper, R.; Diebold, J. Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas. Pathol. Res. Pract. 2000, 196 (7), 469-475.
20. Ikeda, K.; Sakai, K.; Yamamoto, R.; Hareyama, H.; Tsumura, N.; Watari, H.; Shimizu, M.; Minakami, H.; Sakuragi, N. Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer. Int. J. Gynecol. Cancer 2003, 13 (6), 776-784.
21. Martin, L. P.; Hamilton, T. C.; Schilder, R. J. Platinum resistance: the role of DNA repair pathways. Clin. Cancer Res. 2008, 14 (5), 1291-1295.
22. Bowden, N. A. Nucleotide excision repair: Why is it not used to predict response to platinum-based chemotherapy? Cancer Lett. 2014.
23. Gossage, L.; Madhusudan, S. Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat. Rev. 2007, 33 (6), 565-577.
24. Olaussen, K. A.; Dunant, A.; Fouret, P.; Brambilla, E.; Andre, F.; Haddad, V.; Taranchon, E.; Filipits, M.; Pirker, R.; Popper, H. H.; Stahel, R.; Sabatier, L.; Pignon, J. P.; Tursz, T.; Le Chevalier, T.; Soria, J. C. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 2006, 355 (10), 983-991.
25. Muallem, M. Z.; Braicu, I.; Nassir, M.; Richter, R.; Sehouli, J.; Arsenic, R. ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer. Anticancer Res. 2014, 34 (1), 393-399.
26. Zhao, D.; Zhang, W.; Li, X. G.; Wang, X. B.; Li, M.; Li, Y. F.; Tian, H. M.; Song, P. P.; Liu, J.; Chang, Q. Y.; Wu, L. Y. [The mRNA expression of BRCA1, ERCC1, TUBB3, PRR13 genes and their relationship with clinical chemosensitivity in primary epithelial ovarian cancer]. Zhonghua Zhong Liu Za Zhi 2012, 34 (3), 196-200.
27. Rubatt, J. M.; Darcy, K. M.; Tian, C.; Muggia, F.; Dhir, R.; Armstrong, D. K.; Bookman, M. A.; Niedernhofer, L. J.; Deloia, J.; Birrer, M.; Krivak, T. C. Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study. Gynecol. Oncol. 2012, 125 (2), 421-426.
28. Milovic-Kovacevic, M.; Srdic-Rajic, T.; Radulovic, S.; Bjelogrlic, S.; Gavrilovic, D. Expression of ERCC1 protein in biopsy specimen predicts survival in advanced ovarian cancer patients treated with platinum-based chemotherapy. J. BUON 2011, 16 (4), 708-714.
29. Deloia, J. A.; Bhagwat, N. R.; Darcy, K. M.; Strange, M.; Tian, C.; Nuttall, K.; Krivak, T. C.; Niedernhofer, L. J. Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum. Gynecol. Oncol. 2012, 126 (3), 448-454.
30. Chen, P.; Wiencke, J.; Aldape, K.; Kesler-Diaz, A.; Miike, R.; Kelsey, K.; Lee, M.; Liu, J.; Wrensch, M. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol. Biomarkers Prev. 2000, 9 (8), 843-847.
31. Kang, S.; Ju, W.; Kim, J. W.; Park, N. H.; Song, Y. S.; Kim, S. C.; Park, S. Y.; Kang, S. B.; Lee, H. P. Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Exp. Mol. Med. 2006, 38 (3), 320-324.
32. Krivak, T. C.; Darcy, K. M.; Tian, C.; Armstrong, D.; Baysal, B. E.; Gallion, H.; Ambrosone, C. B.; DeLoia, J. A. Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J. Clin. Oncol. 2008, 26 (21), 3598-3606.
33. Kim, H. S.; Kim, M. K.; Chung, H. H.; Kim, J. W.; Park, N. H.; Song, Y. S.; Kang, S. B. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol. Oncol. 2009, 113 (2), 264-269.
34. Fink, D.; Nebel, S.; Norris, P. S.; Aebi, S.; Kim, H. K.; Haas, M.; Howell, S. B. The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells. Br. J. Cancer 1998, 77 (5), 703-708.
35. Scartozzi, M.; De Nictolis, M.; Galizia, E.; Carassai, P.; Bianchi, F.; Berardi, R.; Gesuita, R.; Piga, A.; Cellerino, R.; Porfiri, E. Loss of hMLH1 expression correlates with improved survival in stage III-IV ovarian cancer patients. Eur. J. Cancer 2003, 39 (8), 1144-1149.
36. Chaudhry, P.; Srinivasan, R.; Patel, F. D. Utility of gene promoter methylation in prediction of response to platinum-based chemotherapy in epithelial ovarian cancer (EOC). Cancer Invest. 2009, 27 (8), 877-884.
37. Helleman, J.; van Staveren, I. L.; Dinjens, W. N.; van Kuijk, P. F.; Ritstier, K.; Ewing, P. C.; van der Burg, M. E.; Stoter, G.; Berns, E. M. Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer 2006, 6, 201.
38. Gifford, G.; Paul, J.; Vasey, P. A.; Kaye, S. B.; Brown, R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin. Cancer Res. 2004, 10 (13), 4420-4426.
39. Samimi, G.; Fink, D.; Varki, N. M.; Husain, A.; Hoskins, W. J.; Alberts, D. S.; Howell, S. B. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin. Cancer Res. 2000, 6 (4), 1415-1421.
40. Watanabe, Y.; Koi, M.; Hemmi, H.; Hoshai, H.; Noda, K. A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer. Br. J. Cancer 2001, 85 (7), 1064-1069.
41. Turner, N.; Tutt, A.; Ashworth, A. Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer 2004, 4 (10), 814-819.
42. King, M. C.; Marks, J. H.; Mandell, J. B. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003, 302 (5645), 643-646.
43. Borst, P.; Rottenberg, S.; Jonkers, J. How do real tumors become resistant to cisplatin? Cell Cycle 2008, 7 (10), 1353-1359.
44. Swisher, E. M.; Sakai, W.; Karlan, B. Y.; Wurz, K.; Urban, N.; Taniguchi, T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 2008, 68 (8), 2581-2586.
45. Ben David, Y.; Chetrit, A.; Hirsh-Yechezkel, G.; Friedman, E.; Beck, B. D.; Beller, U.; Ben-Baruch, G.; Fishman, A.; Levavi, H.; Lubin, F.; Menczer, J.; Piura, B.; Struewing, J. P.; Modan, B. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J. Clin. Oncol. 2002, 20 (2), 463-466.
46. Boyd, J.; Sonoda, Y.; Federici, M. G.; Bogomolniy, F.; Rhei, E.; Maresco, D. L.; Saigo, P. E.; Almadrones, L. A.; Barakat, R. R.; Brown, C. L.; Chi, D. S.; Curtin, J. P.; Poynor, E. A.; Hoskins, W. J. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000, 283 (17), 2260-2265.
47. Carser, J. E.; Quinn, J. E.; Michie, C. O.; O'Brien, E. J.; McCluggage, W. G.; Maxwell, P.; Lamers, E.; Lioe, T. F.; Williams, A. R.; Kennedy, R. D.; Gourley, C.; Harkin, D. P. BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer. Gynecol. Oncol. 2011, 123 (3), 492-498.
48. Darcy, K. M.; Birrer, M. J. Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies. Gynecol. Oncol. 2010, 117 (3), 429-439.
49. Weberpals, J. I.; Tu, D.; Squire, J. A.; Amin, M. S.; Islam, S.; Pelletier, L. B.; O'Brien, A. M.; Hoskins, P. J.; Eisenhauer, E. A. Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study. Ann. Oncol. 2011, 22 (11), 2403-2410.
50. Muggia, F.; Safra, T. 'BRCAness' and its implications for platinum action in gynecologic cancer. Anticancer Res. 2014, 34 (2), 551-556.
51. Konstantinopoulos, P. A.; Spentzos, D.; Karlan, B. Y.; Taniguchi, T.; Fountzilas, E.; Francoeur, N.; Levine, D. A.; Cannistra, S. A. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J. Clin. Oncol. 2010, 28 (22), 3555-3561.
52. Mir, R.; Tortosa, A.; Martinez-Soler, F.; Vidal, A.; Condom, E.; Perez-Perarnau, A.; Ruiz-Larroya, T.; Gil, J.; Gimenez-Bonafe, P. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells. Int. J. Cancer 2013, 132 (7), 1525-1536.
53. Righetti, S. C.; Della Torre, G.; Pilotti, S.; Menard, S.; Ottone, F.; Colnaghi, M. I.; Pierotti, M. A.; Lavarino, C.; Cornarotti, M.; Oriana, S.; Bohm, S.; Bresciani, G. L.; Spatti, G.; Zunino, F. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 1996, 56 (4), 689-693.
54. Williams, J.; Lucas, P. C.; Griffith, K. A.; Choi, M.; Fogoros, S.; Hu, Y. Y.; Liu, J. R. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol. Oncol. 2005, 96 (2), 287-295.
55. Hall, J.; Paul, J.; Brown, R. Critical evaluation of p53 as a prognostic marker in ovarian cancer. Expert. Rev. Mol. Med. 2004, 6 (12), 1-20.
56. Yarden, Y.; Sliwkowski, M. X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001, 2 (2), 127-137.
57. Stronach, E. A.; Chen, M.; Maginn, E. N.; Agarwal, R.; Mills, G. B.; Wasan, H.; Gabra, H. DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. Neoplasia 2011, 13 (11), 1069-1080.
58. Hengstler, J. G.; Lange, J.; Kett, A.; Dornhofer, N.; Meinert, R.; Arand, M.; Knapstein, P. G.; Becker, R.; Oesch, F.; Tanner, B. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer. Cancer Res. 1999, 59 (13), 3206-3214.
59. Pfisterer, J.; Du Bois, A.; Bentz, E. K.; Kommoss, F.; Harter, P.; Huober, J.; Schmalfeldt, B.; Burchardi, N.; Arnold, N.; Hilpert, F. Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany. Int. J. Gynecol. Cancer 2009, 19 (1), 109-115.
60. Pinto, D.; Pereira, D.; Portela, C.; da Silva, J. L.; Lopes, C.; Medeiros, R. The influence of HER2 genotypes as molecular markers in ovarian cancer outcome. Biochem. Biophys. Res. Commun. 2005, 335 (4), 1173-1178.
61. Palmieri, C.; Gojis, O.; Rudraraju, B.; Stamp-Vincent, C.; Wilson, D.; Langdon, S.; Gourley, C.; Faratian, D. Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance. Br. J. Cancer 2013, 108 (10), 2039-2044.
62. Kolasa, I. K.; Rembiszewska, A.; Felisiak, A.; Ziolkowska-Seta, I.; Murawska, M.; Moes, J.; Timorek, A.; Dansonka-Mieszkowska, A.; Kupryjanczyk, J. PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biol. Ther. 2009, 8 (1), 21-26.
63. Farley, J.; Smith, L. M.; Darcy, K. M.; Sobel, E.; O'Connor, D.; Henderson, B.; Morrison, L. E.; Birrer, M. J., Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. Cancer Res. 2003, 63 (6), 1235-1241.
64. Parmar, M. K.; Ledermann, J. A.; Colombo, N.; du Bois, A.; Delaloye, J. F.; Kristensen, G. B.; Wheeler, S.; Swart, A. M.; Qian, W.; Torri, V.; Floriani, I.; Jayson, G.; Lamont, A.; Trope, C. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003, 361 (9375), 2099-2106.
65. Trock, B. J.; Leonessa, F.; Clarke, R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J. Natl. Cancer Inst. 1997, 89 (13), 917-931.
66. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2 (1), 48-58.
67. Stordal, B.; Hamon, M.; McEneaney, V.; Roche, S.; Gillet, J. P.; O'Leary, J. J.; Gottesman, M.; Clynes, M. Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by Pglycoprotein. PLoS One 2012, 7 (7), e40717.
68. Mozzetti, S.; Ferlini, C.; Concolino, P.; Filippetti, F.; Raspaglio, G.; Prislei, S.; Gallo, D.; Martinelli, E.; Ranelletti, F. O.; Ferrandina, G.; Scambia, G. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin. Cancer Res. 2005, 11 (1), 298-305.
69. Tian, C.; Ambrosone, C. B.; Darcy, K. M.; Krivak, T. C.; Armstrong, D. K.; Bookman, M. A.; Davis, W.; Zhao, H.; Moysich, K.; Gallion, H.; DeLoia, J. A. Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study. Gynecol. Oncol. 2012, 124 (3), 575-581.
70. Green, H.; Soderkvist, P.; Rosenberg, P.; Horvath, G.; Peterson, C. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin. Cancer Res. 2006, 12 (3 Pt 1), 854-859.
71. Ludwig, A. H.; Kupryjanczyk, J. Does MDR-1 G2677T/A polymorphism really associate with ovarian cancer response to paclitaxel chemotherapy? Clin. Cancer Res. 2006, 12 (20 Pt 1), 6204.
72. Marsh, S.; King, C. R.; McLeod, H. L.; Paul, J.; Gifford, G.; Brown, R. ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer. Clin. Cancer Res. 2006, 12 (13), 4127; author reply 4127-9.
73. Johnatty, S. E.; Beesley, J.; Gao, B.; Chen, X.; Lu, Y.; Law, M. H.; Henderson, M. J.; Russell, A. J.; Hedditch, E. L.; Emmanuel, C.; Fereday, S.; Webb, P. M.; Goode, E. L.; Vierkant, R. A.; Fridley, B. L.; Cunningham, J. M.; Fasching, P. A.; Beckmann, M. W.; Ekici, A. B.; Hogdall, E.; Kjaer, S. K.; Jensen, A.; Hogdall, C.; Brown, R.; Paul, J.; Lambrechts, S.; Despierre, E.; Vergote, I.; Lester, J.; Karlan, B. Y.; Heitz, F.; du Bois, A.; Harter, P.; Schwaab, I.; Bean, Y.; Pejovic, T.; Levine, D. A.; Goodman, M. T.; Camey, M. E.; Thompson, P. J.; Lurie, G.; Shildkraut, J.; Berchuck, A.; Terry, K. L.; Cramer, D. W.; Norris, M. D.; Haber, M.; Macgregor, S.; Defazio, A.; Chenevix-Trench, G. ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol. Oncol. 2013, 131 (1), 8-14.
74. Fracasso, P. M.; Brady, M. F.; Moore, D. H.; Walker, J. L.; Rose, P. G.; Letvak, L.; Grogan, T. M.; McGuire, W. P. Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J. Clin. Oncol. 2001, 19 (12), 2975-2982.
75. Seiden, M. V.; Swenerton, K. D.; Matulonis, U.; Campos, S.; Rose, P.; Batist, G.; Ette, E.; Garg, V.; Fuller, A.; Harding, M. W.; Charpentier, D. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol. Oncol. 2002, 86 (3), 302-310.
76. Orr, G. A.; Verdier-Pinard, P.; McDaid, H.; Horwitz, S. B. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003, 22 (47), 7280-7295.
77. Derry, W. B.; Wilson, L.; Khan, I. A.; Luduena, R. F.; Jordan, M. A. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. Biochemistry 1997, 36 (12), 3554-3562.
78. Hetland, T. E.; Hellesylt, E.; Florenes, V. A.; Trope, C.; Davidson, B.; Kaern, J. Class III beta-tubulin expression in advancedstage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance. Hum. Pathol. 2011, 42 (7), 1019-1026.
79. Ferrandina, G.; Zannoni, G. F.; Martinelli, E.; Paglia, A.; Gallotta, V.; Mozzetti, S.; Scambia, G.; Ferlini, C. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin. Cancer Res. 2006, 12 (9), 2774-2779.
80. Gao, S.; Zhao, X.; Lin, B.; Hu, Z.; Yan, L.; Gao, J. Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance. Tumour Biol. 2012, 33 (5), 1759-1765.
81. Roque, D. M.; Bellone, S.; English, D. P.; Buza, N.; Cocco, E.; Gasparrini, S.; Bortolomai, I.; Ratner, E.; Silasi, D. A.; Azodi, M.; Rutherford, T. J.; Schwartz, P. E.; Santin, A. D. Tubulin-beta-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. Cancer 2013, 119 (14), 2582-2592.
82. Dumontet, C.; Jordan, M. A.; Lee, F. F. Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies. Mol. Cancer Ther. 2009, 8 (1), 17-25.
83. Rivera, E.; Gomez, H. Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast cancer research: BCR 2010, 12 Suppl 2, S2.
84. Green, H.; Rosenberg, P.; Soderkvist, P.; Horvath, G.; Peterson, C. beta-Tubulin mutations in ovarian cancer using single strand conformation analysis-risk of false positive results from paraffin embedded tissues. Cancer Lett. 2006, 236 (1), 148-154.
85. Rouzier, R.; Perou, C. M.; Symmans, W. F.; Ibrahim, N.; Cristofanilli, M.; Anderson, K.; Hess, K. R.; Stec, J.; Ayers, M.; Wagner, P.; Morandi, P.; Fan, C.; Rabiul, I.; Ross, J. S.; Hortobagyi, G. N.; Pusztai, L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 2005, 11 (16), 5678-5685.
86. Modi, S.; DiGiovanna, M. P.; Lu, Z.; Moskowitz, C.; Panageas, K. S.; Van Poznak, C.; Hudis, C. A.; Norton, L.; Tan, L.; Stern, D. F.; Carter, D.; Seidman, A. D. Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Cancer Invest. 2005, 23 (6), 483-487.
87. Carter, S. L.; Eklund, A. C.; Kohane, I. S.; Harris, L. N.; Szallasi, Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat. Genet. 2006, 38 (9), 1043-1048.
88. Swanton, C.; Nicke, B.; Schuett, M.; Eklund, A. C.; Ng, C.; Li, Q.; Hardcastle, T.; Lee, A.; Roy, R.; East, P.; Kschischo, M.; Endesfelder, D.; Wylie, P.; Kim, S. N.; Chen, J. G.; Howell, M.; Ried, T.; Habermann, J. K.; Auer, G.; Brenton, J. D.; Szallasi, Z.; Downward, J. Chromosomal instability determines taxane response. Proc. Natl. Acad. Sci. U. S. A. 2009, 106 (21), 8671-8676.
89. Halon, A.; Nowak-Markwitz, E.; Donizy, P.; Matkowski, R.; Maciejczyk, A.; Gansukh, T.; Gyorffy, B.; Spaczynski, M.; Zabel, M.; Lage, H.; Surowiak, P. Enhanced immunoreactivity of TIMP-2 in the stromal compartment of tumor as a marker of favorable prognosis in ovarian cancer patients. J. Histochem. Cytochem. 2012, 60 (7), 491-501.
90. Serkies, K.; Sinacki, M.; Jassem, J. The role of hormonal factors and endocrine therapy in ovarian cancer. Contemporary Oncology 2013, 17 (1), 14-19.
91. Markman, M.; Bookman, M. A. Second-line treatment of ovarian cancer. Oncologist 2000, 5 (1), 26-35.
92. Fekete, T.; Raso, E.; Pete, I.; Tegze, B.; Liko, I.; Munkacsy, G.; Sipos, N.; Rigo, J., Jr.; Gyorffy, B. Meta-analysis of gene expression profiles associated with histological classification and survival in 829 ovarian cancer samples. Int. J. Cancer 2012, 131 (1), 95-105.
93. Hatch, K. D.; Beecham, J. B.; Blessing, J. A.; Creasman, W. T. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 1991, 68 (2), 269-271.
94. Papadimitriou, C. A.; Markaki, S.; Siapkaras, J.; Vlachos, G.; Efstathiou, E.; Grimani, I.; Hamilos, G.; Zorzou, M.; Dimopoulos, M. A. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology 2004, 66 (2), 112-117.
95. Halon, A.; Nowak-Markwitz, E.; Maciejczyk, A.; Pudelko, M.; Gansukh, T.; Gyorffy, B.; Donizy, P.; Murawa, D.; Matkowski, R.; Spaczynski, M.; Lage, H.; Surowiak, P. Loss of estrogen receptor beta expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients. Anticancer Res. 2011, 31 (2), 711-718.
96. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 2011, 144 (5), 646-674.
97. Sharma, P. S.; Sharma, R.; Tyagi, T. VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future. Curr. Cancer Drug Targets 2011, 11 (5), 624-653.
98. Cooper, B. C.; Ritchie, J. M.; Broghammer, C. L.; Coffin, J.; Sorosky, J. I.; Buller, R. E.; Hendrix, M. J.; Sood, A. K. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin. Cancer Res. 2002, 8 (10), 3193-3197.
99. Gavalas, N. G.; Liontos, M.; Trachana, S. P.; Bagratuni, T.; Arapinis, C.; Liacos, C.; Dimopoulos, M. A.; Bamias, A. Angiogenesis-related pathways in the pathogenesis of ovarian cancer. Int. J. Mol. Sci. 2013, 14 (8), 15885-15909.
100. Burger, R. A.; Brady, M. F.; Bookman, M. A.; Fleming, G. F.; Monk, B. J.; Huang, H.; Mannel, R. S.; Homesley, H. D.; Fowler, J.; Greer, B. E.; Boente, M.; Birrer, M. J.; Liang, S. X. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 2011, 365 (26), 2473-2483.
101. Perren, T. J.; Swart, A. M.; Pfisterer, J.; Ledermann, J. A.; Pujade- Lauraine, E.; Kristensen, G.; Carey, M. S.; Beale, P.; Cervantes, A.; Kurzeder, C.; du Bois, A.; Sehouli, J.; Kimmig, R.; Stahle, A.; Collinson, F.; Essapen, S.; Gourley, C.; Lortholary, A.; Selle, F.; Mirza, M. R.; Leminen, A.; Plante, M.; Stark, D.; Qian, W.; Parmar, M. K.; Oza, A. M. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 2011, 365 (26), 2484-2496.
102. Aghajanian, C.; Blank, S. V.; Goff, B. A.; Judson, P. L.; Teneriello, M. G.; Husain, A.; Sovak, M. A.; Yi, J.; Nycum, L. R. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J. Clin. Oncol. 2012, 30 (17), 2039-2045.
103. Pujade-Lauraine, E.; Hilpert, F.; Weber, B.; Reuss, A.; Poveda, A.; Kristensen, G.; Sorio, R.; Vergote, I. B.; Witteveen, P.; Bamias, A.; Pereira, D.; Wimberger, P.; Oaknin, A.; Mirza, M. R.; Follana, P.; Bollag, D. T.; Ray-Coquard, I. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). JCO 2012.
104. Morgan, R. J.; Alvarez, R. D.; Armstrong, D. K.; Burger, R. A.; Castells, M.; Chen, L. M.; Copeland, L.; Crispens, M. A.; Gershenson, D.; Gray, H.; Hakam, A.; Havrilesky, L. J.; Johnston, C.; Lele, S.; Martin, L.; Matulonis, U. A.; O'Malley, D. M.; Penson, R. T.; Remmenga, S. W.; Sabbatini, P.; Santoso, J. T.; Schilder, R. J.; Schink, J.; Teng, N.; Werner, T. L.; Hughes, M.; Dwyer, M. A. Ovarian Cancer, Version 3.2012. J. Natl. Compr. Canc. Netw. 2012, 10 (11), 1339-1349.
105. Pinilla-Dominguez, P.; Richardson, J.; Robertson, J.; Adam, J. NICE guidance on bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinumsensitive advanced ovarian cancer. Lancet Oncol. 2013, 14 (8), 691-692.
106. Sennino, B.; McDonald, D. M. Controlling escape from angiogenesis inhibitors. Nat. Rev. Cancer 2012, 12 (10), 699-709.
107. Van Cutsem, E.; de Haas, S.; Kang, Y. K.; Ohtsu, A.; Tebbutt, N. C.; Ming Xu, J.; Peng Yong, W.; Langer, B.; Delmar, P.; Scherer, S. J.; Shah, M. A. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J. Clin. Oncol. 2012, 30 (17), 2119-2127.
108. Smerdel, M. P.; Steffensen, K. D.; Waldstrom, M.; Brandslund, I.; Jakobsen, A. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Gynecol. Oncol. 2010, 118 (2), 167-171.
109. Madsen, C. V.; Steffensen, K. D.; Olsen, D. A.; Waldstrom, M.; Adimi, P.; Smerdel, M.; Brandslund, I.; Jakobsen, A. Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab. J. Ovarian Res. 2012, 5 (1), 23.
110. Lambrechts, D.; Claes, B.; Delmar, P.; Reumers, J.; Mazzone, M.; Yesilyurt, B. T.; Devlieger, R.; Verslype, C.; Tejpar, S.; Wildiers, H.; de Haas, S.; Carmeliet, P.; Scherer, S. J.; Van Cutsem, E. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol. 2012, 13 (7), 724-733.
111. Schultheis, A. M.; Lurje, G.; Rhodes, K. E.; Zhang, W.; Yang, D.; Garcia, A. A.; Morgan, R.; Gandara, D.; Scudder, S.; Oza, A.; Hirte, H.; Fleming, G.; Roman, L.; Lenz, H. J. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin. Cancer Res. 2008, 14 (22), 7554-7563.
112. Osterlund, P.; Soveri, L. M.; Isoniemi, H.; Poussa, T.; Alanko, T.; Bono, P. Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br. J. Cancer 2011, 104 (4), 599-604.
113. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474 (7353), 609-615.
114. Chan, S. L.; Mok, T. PARP inhibition in BRCA-mutated breast and ovarian cancers. Lancet 2010, 376 (9737), 211-213.
115. Fong, P. C.; Yap, T. A.; Boss, D. S.; Carden, C. P.; Mergui- Roelvink, M.; Gourley, C.; De Greve, J.; Lubinski, J.; Shanley, S.; Messiou, C.; A'Hern, R.; Tutt, A.; Ashworth, A.; Stone, J.; Carmichael, J.; Schellens, J. H.; de Bono, J. S.; Kaye, S. B. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 2010, 28 (15), 2512-2519.
116. Audeh, M. W.; Carmichael, J.; Penson, R. T.; Friedlander, M.; Powell, B.; Bell-McGuinn, K. M.; Scott, C.; Weitzel, J. N.; Oaknin, A.; Loman, N.; Lu, K.; Schmutzler, R. K.; Matulonis, U.; Wickens, M.; Tutt, A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376 (9737), 245-251.
117. Infante, J. R.; Burris, H. A., 3rd. PARP inhibitors: pitfalls and promises. Lancet Oncol. 2013, 14 (9), 798-799.
118. Sandhu, S. K.; Schelman, W. R.; Wilding, G.; Moreno, V.; Baird, R. D.; Miranda, S.; Hylands, L.; Riisnaes, R.; Forster, M.; Omlin, A.; Kreischer, N.; Thway, K.; Gevensleben, H.; Sun, L.; Loughney, J.; Chatterjee, M.; Toniatti, C.; Carpenter, C. L.; Iannone, R.; Kaye, S. B.; de Bono, J. S.; Wenham, R. M. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 doseescalation trial. Lancet Oncol. 2013, 14 (9), 882-892.
119. De Bono, J. S.; Mina, L. A.; Gonzalez, M.; Curtin, N. J.; Wang, E.; Henshaw, J. W.; Chadha, M.; Sachdev, J. C.; Matei, D.; Jameson, G. S.; Ong, M.; Basu, B.; Wainberg, Z. A.; Byers, L. A.; Chugh, R.; Dorr, A.; Kaye, S. B.; Ramanathan, R. K. First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. J. Clin. Oncol. 2013, 31 (suppl; abstr 2580).
120. Mukhopadhyay, A.; Elattar, A.; Cerbinskaite, A.; Wilkinson, S. J.; Drew, Y.; Kyle, S.; Los, G.; Hostomsky, Z.; Edmondson, R. J.; Curtin, N. J. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin. Cancer Res. 2010, 16 (8), 2344-2351.
121. Hayat, M. J.; Howlader, N.; Reichman, M. E.; Edwards, B. K. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007, 12 (1), 20-37.
122. Perets, R.; Wyant, G. A.; Muto, K. W.; Bijron, J. G.; Poole, B. B.; Chin, K. T.; Chen, J. Y.; Ohman, A. W.; Stepule, C. D.; Kwak, S.; Karst, A. M.; Hirsch, M. S.; Setlur, S. R.; Crum, C. P.; Dinulescu, D. M.; Drapkin, R. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 2013, 24 (6), 751-765.
123. Reade, C. J.; McVey, R. M.; Tone, A. A.; Finlayson, S. J.; McAlpine, J. N.; Fung-Kee-Fung, M.; Ferguson, S. E. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift. J. Obstet. Gynaecol. Can. 2014, 36 (2), 133-140.
124. Singer, G.; Oldt, R., 3rd; Cohen, Y.; Wang, B. G.; Sidransky, D.; Kurman, R. J.; ShihIe, M. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl. Cancer Inst. 2003, 95 (6), 484-486.
125. Lassus, H.; Sihto, H.; Leminen, A.; Joensuu, H.; Isola, J.; Nupponen, N. N.; Butzow, R. Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J. Mol. Med. 2006, 84 (8), 671-81.
126. Gershenson, D. M.; Sun, C. C.; Bodurka, D.; Coleman, R. L.; Lu, K. H.; Sood, A. K.; Deavers, M.; Malpica, A. L.; Kavanagh, J. J. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol. Oncol. 2009, 114 (1), 48-52.
127. Despierre, E.; Yesilyurt, B. T.; Lambrechts, S.; Johnson, N.; Verheijen, R.; van der Burg, M.; Casado, A.; Rustin, G.; Berns, E.; Leunen, K.; Amant, F.; Moerman, P.; Lambrechts, D.; Vergote, I. Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment. Int. J. Gynecol. Cancer 2014, 24 (3), 468-477.
128. Miller, C. R.; Oliver, K. E.; Farley, J. H. MEK1/2 inhibitors in the treatment of gynecologic malignancies. Gynecol. Oncol. 2014.
129. Farley, J.; Brady, W. E.; Vathipadiekal, V.; Lankes, H. A.; Coleman, R.; Morgan, M. A.; Mannel, R.; Yamada, S. D.; Mutch, D.; Rodgers, W. H.; Birrer, M.; Gershenson, D. M. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013, 14 (2), 134-140.
130. Husseinzadeh, N.; Husseinzadeh, H. D. mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: A critical review. Gynecol. Oncol. 2014.
131. Fraser, M.; Bai, T.; Tsang, B. K. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int. J. Cancer 2008, 122 (3), 534-546.
132. Behbakht, K.; Sill, M. W.; Darcy, K. M.; Rubin, S. C.; Mannel, R. S.; Waggoner, S.; Schilder, R. J.; Cai, K. Q.; Godwin, A. K.; Alpaugh, R. K. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol. Oncol. 2011, 123 (1), 19-26.
133. Fotopoulou, C.; Vergote, I.; Mainwaring, P.; Bidzinski, M.; Vermorken, J. B.; Ghamande, S. A.; Harnett, P.; Del Prete, S. A.; Green, J. A.; Spaczynski, M.; Blagden, S.; Gore, M.; Ledermann, J.; Kaye, S.; Gabra, H. Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study. Ann. Oncol. 2014, 25 (1), 160-165.
134. Ma, Y.; Ding, Z.; Qian, Y.; Shi, X.; Castranova, V.; Harner, E. J.; Guo, L. Predicting cancer drug response by proteomic profiling. Clin. Cancer Res. 2006, 12 (15), 4583-4589.
135. He, J.; Shen, D.; Chung, D. U.; Saxton, R. E.; Whitelegge, J. P.; Faull, K. F.; Chang, H. R. Tumor proteomic profiling predicts the susceptibility of breast cancer to chemotherapy. Int. J. Oncol. 2009, 35 (4), 683-692.
136. Vergara, D.; Tinelli, A.; Iannone, A.; Maffia, M. The impact of proteomics in the understanding of the molecular basis of Paclitaxel-resistance in ovarian tumors. Curr. Cancer Drug Targets 2012, 12 (8), 987-997.
137. Rutherford, T.; Orr, J., Jr.; Grendys, E., Jr.; Edwards, R.; Krivak, T. C.; Holloway, R.; Moore, R. G.; Puls, L.; Tillmanns, T.; Schink, J. C.; Brower, S. L.; Tian, C.; Herzog, T. J. A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer. Gynecol. Oncol. 2013.
138. Krivak, T. C.; Lele, S.; Richard, S.; Alvarez Secord, A.; Leath, C. A., 3rd; Brower, S. L.; Tian, C.; Moore, R. G. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer. Am. J. Obstet. Gynecol. 2014.
139. Vecchione, A.; Belletti, B.; Lovat, F.; Volinia, S.; Chiappetta, G.; Giglio, S.; Sonego, M.; Cirombella, R.; Onesti, E. C.; Pellegrini, P.; Califano, D.; Pignata, S.; Losito, S.; Canzonieri, V.; Sorio, R.; Alder, H.; Wernicke, D.; Stoppacciaro, A.; Baldassarre, G.; Croce, C. M. A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 2013, 110 (24), 9845-9850.
140. Frederick, P.; Green, H.; Huang, J.; Egger, M.; Frieboes, H.; Grizzle, W.; McNally, L. Chemoresistance in ovarian cancer linked to expression of microRNAs. Biotech. Histochem. 2013, 88 (7), 403-409.
141. Chan, J. K.; Blansit, K.; Kiet, T.; Sherman, A.; Wong, G.; Earle, C.; Bourguignon, L. Y. The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer. Gynecol. Oncol. 2014.
142. Xiang, Y.; Ma, N.; Wang, D.; Zhang, Y.; Zhou, J.; Wu, G.; Zhao, R.; Huang, H.; Wang, X.; Qiao, Y.; Li, F.; Han, D.; Wang, L.; Zhang, G.; Gao, X. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene 2014, 33 (3), 378-386.
143. Zhu, X.; Li, Y.; Xie, C.; Yin, X.; Liu, Y.; Cao, Y.; Fang, Y.; Lin, X.; Xu, Y.; Xu, W.; Shen, H.; Wen, J. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6. Int. J. Cancer 2014.
144. Huh, J. H.; Kim, T. H.; Kim, K.; Song, J. A.; Jung, Y. J.; Jeong, J. Y.; Lee, M. J.; Kim, Y. K.; Lee, D. H.; An, H. J. Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer. Br. J. Cancer 2013, 109 (2), 452-461.
145. Wan, Y. W.; Mach, C. M.; Allen, G. I.; Anderson, M. L.; Liu, Z. On the reproducibility of TCGA ovarian cancer microRNA profiles. PLoS One 2014, 9 (1), e87782.
146. Pusztai, L.; Hatzis, C.; Andre, F. Reproducibility of research and preclinical validation: problems and solutions. Nature Rev. Clin. Oncol. 2013, 10 (12), 720-724.
147. Kim, Y.; Guntupalli, S. R.; Lee, S. J.; Behbakht, K.; Theodorescu, D.; Lee, J. K.; Diamond, J. R. Retrospective analysis of survival improvement by molecular biomarker-based personalized chemotherapy for recurrent ovarian cancer. PLoS One 2014, 9 (2), e86532.
148. Gyorffy, B.; Lanczky, A.; Szallasi, Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr. Relat. Cancer 2012, 19 (2), 197-208.
149. Gyorffy, B.; Dietel, M.; Fekete, T.; Lage, H. A snapshot of microarray-generated gene expression signatures associated with ovarian carcinoma. Int. J. Gynecol. Cancer 2008, 18 (6), 1215-1233.
150. Ferriss, J. S.; Kim, Y.; Duska, L.; Birrer, M.; Levine, D. A.; Moskaluk, C.; Theodorescu, D.; Lee, J. K. Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance. PLoS One 2012, 7 (2), e30550.
151. Liu, Y.; Sun, Y.; Broaddus, R.; Liu, J.; Sood, A. K.; Shmulevich, I.; Zhang, W. Integrated analysis of gene expression and tumor nuclear image profiles associated with chemotherapy response in serous ovarian carcinoma. PLoS One 2012, 7 (5), e36383.
152. Denkert, C.; Budczies, J.; Darb-Esfahani, S.; Gyorffy, B.; Sehouli, J.; Konsgen, D.; Zeillinger, R.; Weichert, W.; Noske, A.; Buckendahl, A. C.; Muller, B. M.; Dietel, M.; Lage, H. A prognostic gene expression index in ovarian cancer-validation across different independent data sets. J. Pathol. 2009, 218 (2), 273-280.